AD 301
Alternative Names: AD-301Latest Information Update: 28 Jan 2024
At a glance
- Originator Addpharma
- Class Hepatoprotectants
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Non-alcoholic steatohepatitis
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for phase-I development in Non-alcoholic-steatohepatitis in South Korea
- 17 Dec 2020 AD 301 is available for licensing as of 17 Dec 2020. http://www.addpharma.co.kr/
- 17 Dec 2020 Phase-I clinical trials in Non-alcoholic steatohepatitis in South Korea (unspecified route) (Addpharma pipeline, December 2020)